New hope for hard-to-treat breast cancer: immune-boosting combos tested
NCT ID NCT03971409
First seen Apr 20, 2026 · Last updated May 09, 2026 · Updated 2 times
Summary
This study tests whether combining an immunotherapy drug (avelumab) with other targeted drugs can shrink or control advanced triple-negative breast cancer that has spread or come back. About 145 adults with stage IV or inoperable breast cancer are taking part. The goal is to see if these combinations work better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Georgetown University
Washington D.C., District of Columbia, 20057, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
O'Neal Comprehensive Cancer Center
Birmingham, Alabama, 35294, United States
-
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Baltimore, Maryland, 21218, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Chicago Medicine Comprehensive Cancer Center
Evergreen Park, Illinois, 60805, United States
-
Vanderbilt University Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.